Research graph
References from Tumor-derived acetylcholine promotes immune evasion in hepatocellular carcinoma by protecting regulatory T cells from ferroptosis. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 · External reference
Advances in the treatment of hepatocellular carcinoma: an overview of the current and evolving therapeutic landscape for clinicians
2025 · External reference
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
10.1056/nejmoa1915745 · 2020 · External reference
Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: a global-scale, cross-sectional, and large-sample informatics study
10.1097/js9.0000000000001479 · 2024 · External reference
Regulatory T cells and immune escape in hepatocellular carcinoma: understanding the tumor microenvironment and advancing CAR-T cell therapy
10.3389/fimmu.2024.1431211 · 2024 · External reference
Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection
10.1200/jco.2006.09.4565 · 2007 · External reference
Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients
10.1053/j.gastro.2007.03.102 · 2007 · External reference
Ferroptosis: mechanisms, biology and role in disease
10.1038/s41580-020-00324-8 · 2021 · External reference
Current progress of ferroptosis study in hepatocellular carcinoma
10.7150/ijbs.96014 · 2024 · External reference
Mechanism of sorafenib resistance associated with ferroptosis in hepatocellular carcinoma
10.3389/fphar.2023.1207496 · 2023 · External reference
The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity
10.1016/j.celrep.2021.109235 · 2021 · External reference
CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy
10.1038/s41586-019-1170-y · 2019 · External reference
FSP1 is a glutathione-independent ferroptosis suppressor
10.1038/s41586-019-1707-0 · 2019 · External reference
The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis
10.1038/s41586-019-1705-2 · 2019 · External reference
Nicotinic acetylcholine receptors in cancer: multiple roles in proliferation and inhibition of apoptosis
10.1016/j.tips.2007.12.006 · 2008 · External reference
Contributions of non-neuronal cholinergic systems to the regulation of immune cell function, highlighting the role of α7 nicotinic acetylcholine receptors
10.3390/ijms25084564 · 2024 · External reference
α7nAChR-mediated recruitment of PP1γ promotes TRAF6/NF-κB cascade to facilitate the progression of hepatocellular carcinoma
10.1002/mc.22885 · 2018 · External reference
Stimulation of α7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro
10.1124/jpet.110.169961 · 2010 · External reference
Distinct roles of α7 nAChRs in antigen-presenting cells and CD4+ T cells in the regulation of T cell differentiation
10.3389/fimmu.2019.01102 · 2019 · External reference
Deciphering STAT3 signaling potential in hepatocellular carcinoma: tumorigenesis, treatment resistance, and pharmacological significance
10.1186/s11658-023-00438-9 · 2023 · External reference
The deubiquitinase USP11 regulates cell proliferation and ferroptotic cell death via stabilization of NRF2
10.1038/s41388-021-01660-5 · 2021 · External reference
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer
10.1016/j.immuni.2013.10.003 · 2013 · External reference
Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade
10.1016/j.celrep.2016.12.019 · 2017 · External reference
The lactate-primed KAT8-PCK2 axis exacerbates hepatic ferroptosis during ischemia/reperfusion injury by reprogramming OXSM-dependent mitochondrial fatty acid synthesis
2025 · External reference
HDLBP-stabilized lncFAL inhibits ferroptosis vulnerability by diminishing Trim69-dependent FSP1 degradation in hepatocellular carcinoma
10.1016/j.redox.2022.102546 · 2022 · External reference
A novel medication decision gene signature predicts response to individualized therapy and prognosis outcomes in hepatocellular carcinoma patients
10.3389/fimmu.2022.990571 · 2022 · External reference
α7nAChR activation promotes the generation of Treg cells by enhancing the dephosphorylation of Foxo1 via the IP3R/Ca2+/calcineurin pathway
10.1016/j.bcp.2025.117290 · 2025 · External reference
CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner
10.1126/science.1172702 · 2009 · External reference
Hepatocellular carcinoma
10.1038/s41572-020-00240-3 · 2021 · External reference
Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
10.1016/j.jhep.2021.11.030 · 2022 · External reference
Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma
2023 · External reference
Current insights into the hepatic microenvironment and immunotherapy in hepatocellular carcinoma
2023 · External reference
FSP1: a key regulator of ferroptosis
10.1016/j.molmed.2023.05.013 · 2023 · External reference
Phase separation of FSP1 promotes ferroptosis
10.1038/s41586-023-06255-6 · 2023 · External reference
Sorafenib induces ferroptosis by promoting TRIM54-mediated FSP1 ubiquitination and degradation in hepatocellular carcinoma
10.1097/hc9.0000000000000246 · 2023 · External reference
EBF1-induced CSRP2 boosts the progression of B-cell acute lymphocytic leukemia by inhibiting ferroptosis
10.1016/j.canlet.2025.217556 · 2025 · External reference
Targeting ferroptosis suppressor protein 1 for overcoming ferroptosis resistance
2023 · External reference
USP11 is involved in the sensitivity of liver cancer cells to ferroptosis and taxanes through the regulation of NRF2 ubiquitin-mediated degradation
10.1016/j.tranon.2025.102553 · 2025 · External reference
Regulatory T cells in cancer immunotherapy
10.1038/cr.2016.151 · 2017 · External reference
Therapeutic targeting of regulatory T cells in cancer
10.1016/j.trecan.2022.06.008 · 2022 · External reference
The role of regulatory T cells in cancer treatment resistance
10.3390/ijms241814114 · 2023 · External reference
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
10.1016/j.ccell.2023.02.014 · 2023 · External reference
Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma
10.1053/j.gastro.2022.09.005 · 2023 · External reference
Anti-PD-1/PD-L1 based combination immunotherapy to boost antigen-specific CD8+ T cell response in hepatocellular carcinoma
10.3390/cancers13081922 · 2021 · External reference
The complexity of the tumor microenvironment in hepatocellular carcinoma and emerging therapeutic developments
10.3390/jcm12237469 · 2023 · External reference
Neuroimmune nexus in the pathophysiology and therapy of inflammatory disorders: role of α7 nicotinic acetylcholine receptors
10.1016/j.phrs.2023.106758 · 2023 · External reference
Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside
10.1186/s40164-024-00539-x · 2024 · External reference
Immunotherapies for hepatocellular carcinoma
10.1038/s41571-021-00573-2 · 2022 · External reference
Targeting regulatory T cell metabolism in disease: novel therapeutic opportunities
10.1002/eji.202250002 · 2023 · External reference
Ferroptosis in cancer immunity and immunotherapy: multifaceted interplay and clinical implications
10.1016/j.cytogfr.2023.08.004 · 2024 · External reference
Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives
10.1186/s13045-024-01549-2 · 2024 · External reference
